Search

Your search keyword '"Leung, Bonnie W."' showing total 20 results
Start Over Author "Leung, Bonnie W." Publication Year Range Last 50 years
20 results on '"Leung, Bonnie W."'

1. Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma

Author

Wan, Guihong, Leung, Bonnie W., DeSimone, Mia S., Nguyen, Nga, Rajeh, Ahmad, Collier, Michael R., Rashdan, Hannah, Roster, Katie, Zhou, Xu, Moseley, Cameron B., Nirmal, Ajit J., Pelletier, Roxanne J., Maliga, Zoltan, Marko-Varga, Gyorgy, Németh, István Balázs, Tsao, Hensin, Asgari, Maryam M., Gusev, Alexander, Stagner, Anna M., Lian, Christine G., Hurlbert, Marc S., Liu, Feng, Yu, Kun-Hsing, Sorger, Peter K., and Semenov, Yevgeniy R.

Published
2024
Full Text
View/download PDF

2. Prediction of early-stage melanoma recurrence using clinical and histopathologic features

Author

Wan, Guihong, Nguyen, Nga, Liu, Feng, DeSimone, Mia S., Leung, Bonnie W., Rajeh, Ahmad, Collier, Michael R., Choi, Min Seok, Amadife, Munachimso, Tang, Kimberly, Zhang, Shijia, Phillipps, Jordan S., Jairath, Ruple, Alexander, Nora A., Hua, Yining, Jiao, Meng, Chen, Wenxin, Ho, Diane, Duey, Stacey, Németh, István Balázs, Marko-Varga, Gyorgy, Valdés, Jeovanis Gil, Liu, David, Boland, Genevieve M., Gusev, Alexander, Sorger, Peter K., Yu, Kun-Hsing, and Semenov, Yevgeniy R.

Published
2022
Full Text
View/download PDF

3. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.

Author

Wan, Guihong, Khattab, Sara, Leung, Bonnie W, Zhang, Shijia, Nguyen, Nga, Tran, Matthew, Lin, Chuck, Chang, Crystal, Alexander, Nora, Jairath, Ruple, Phillipps, Jordan, Tang, Kimberly, Rajeh, Ahmad, Zubiri, Leyre, Chen, Steven T, Demehri, Shadmehr, Yu, Kun-Hsing, Gusev, Alexander, Kwatra, Shawn G, and LeBoeuf, Nicole R

Subjects
DERMATOTOXICOLOGY, HEAD & neck cancer, PROPORTIONAL hazards models, DRUG side effects, COHORT analysis, TRANSITIONAL cell carcinoma
Abstract

Background Cutaneous immune-related adverse events (cirAEs) are the most common toxicities to occur in the setting of immune checkpoint inhibitor (ICI) therapy. Identifying patients who are at increased risk of developing cirAEs may improve quality of life and outcomes. Objectives To investigate the influence of cancer type and histology on the development of cirAEs in the setting of ICI therapy and survival outcomes. Methods This retrospective cohort study included patients recruited between 1 December 2011 and 30 October 2020. They received ICI from 2011 to 2020 with follow-up of outcomes through October 2021. We identified 3668 recipients of ICI therapy who were seen at Massachusetts General Brigham and Dana-Farber. Of these, 669 developed cirAEs. Records that were incomplete or categories of insufficient sample size were excluded from the study cohort. Multivariate Cox proportional hazards models were used to investigate the impact of cancer organ system and histology on cirAE development, after adjusting for demographics, Charlson Comorbidity Index, ICI type, cancer stage at ICI initiation, and year of ICI initiation. Time-varying Cox proportional hazards modelling was used to examine the impact of cirAE development on mortality. Results Compared with other nonepithelial cancers (neuroendocrine, leukaemia, lymphoma, myeloma, sarcoma and central nervous system malignancies), cutaneous squamous cell carcinoma [cSCC; hazard ratio (HR) 3.57, P < 0.001], melanoma (HR 2.09, P < 0.001), head and neck adenocarcinoma (HR 2.13, P = 0.009), genitourinary transitional cell carcinoma (HR 2.15, P < 0.001) and genitourinary adenocarcinoma (HR 1.53, P = 0.037) were at significantly higher risk of cirAEs in multivariate analyses. The increased risk of cirAEs translated into an adjusted survival benefit for melanoma (HR 0.37, P < 0.001) and cSCC (HR 0.51, P = 0.011). Conclusions The highest rate of cirAEs and subsequent survival benefits were observed in cutaneous malignancies treated with ICI therapies. This study improves our understanding of patients who are at highest risk of developing cirAEs and would, therefore, benefit from appropriate counselling and closer monitoring by their oncologists and dermatologists throughout their ICI therapy. Limitations include its retrospective nature and cohort from one geography. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional study

Author

Roster, Katie, primary, Rajeh, Ahmad, additional, Nguyen, Nga, additional, Tang, Kimberly, additional, Zhang, Shijia, additional, Rashdan, Hannah, additional, Wan, Guihong, additional, Leung, Bonnie W., additional, Khattab, Sara, additional, Chen, Steven, additional, LeBoeuf, Nicole R., additional, and Semenov, Yevgeniy R., additional

Published
2024
Full Text
View/download PDF

5. 1273 Effect of systemic immunosuppression timing on overall survival among immune checkpoint inhibitor recipients

Author

Wan, Guihong, primary, Nguyen, Nga, additional, Yan, Boshen, additional, Amadife, Munachimso, additional, Leung, Bonnie W, additional, Tang, Kimberly, additional, Zhang, Shijia, additional, Klebanov, Nikolai, additional, Liu, Feng, additional, Boland, Genevieve M, additional, Leboeuf, Nicole R, additional, Kwatra, Shawn, additional, Yu, Kun-Hsing, additional, Gusev, Alexander, additional, and Semenov, Yevgeniy R, additional

Published
2023
Full Text
View/download PDF

6. 554 Clinical outcomes of patients treated with immune checkpoint inhibitor therapy for early-stage melanoma recurrence: a retrospective cohort study

Author

Nguyen, Nga, primary, Wan, Guihong, additional, Rashdan, Hannah, additional, Leung, Bonnie W, additional, Phillips, Jordan, additional, Yan, Boshen, additional, Rajesh, Ahmad, additional, Collier, Michael R, additional, Tang, Kimberly, additional, Choi, Min Seok, additional, Alexander, Nora A, additional, Jairath, Ruple, additional, Kwatra, Shawn, additional, DeSimone, Mia S, additional, and Semenov, Yevgeniy R, additional

Published
2023
Full Text
View/download PDF

7. Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma

Author

Wan, Guihong, primary, Leung, Bonnie W., additional, DeSimone, Mia S., additional, Nguyen, Nga, additional, Rajeh, Ahmad, additional, Collier, Michael R., additional, Rashdan, Hannah, additional, Roster, Katie, additional, Zhou, Xu, additional, Moseley, Cameron B., additional, Nirmal, Ajit J., additional, Pelletier, Roxanne J., additional, Maliga, Zoltan, additional, Marko-Varga, Gyorgy, additional, Németh, István Balázs, additional, Tsao, Hensin, additional, Asgari, Maryam M., additional, Gusev, Alexander, additional, Stagner, Anna M., additional, Lian, Christine G., additional, Hurlbert, Marc S., additional, Liu, Feng, additional, Yu, Kun-Hsing, additional, Sorger, Peter K., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

8. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study

Author

Wan, Guihong, primary, Nguyen, Nga, additional, Leung, Bonnie W., additional, Rashdan, Hannah, additional, Tang, Kimberly, additional, Roster, Katie, additional, Collier, Michael R., additional, Ugwu-Dike, Pearl O., additional, Raval, Neel S., additional, Alexander, Nora A., additional, Jairath, Ruple, additional, Phillipps, Jordan, additional, Amadife, Munachimso, additional, Zhang, Shijia, additional, Gusev, Alexander, additional, Chen, Steven T., additional, Reynolds, Kerry L., additional, LeBoeuf, Nicole R., additional, Kwatra, Shawn G., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

10. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study

Author

Wan, Guihong C., primary, Nguyen, Nga, additional, Leung, Bonnie W., additional, Rashdan, Hannah, additional, Tang, Kimberly, additional, Roster, Katie, additional, Collier, Michael R., additional, Ugwu-Dike, Pearl O., additional, Raval, Neel S., additional, Alexander, Nora A., additional, Jairath, Ruple, additional, Phillipps, Jordan, additional, Amadife, Munachimso, additional, Zhang, Shijia, additional, Gusev, Alexander, additional, Chen, Steven T., additional, Reynolds, Kerry L., additional, LeBoeuf, Nicole R., additional, Kwatra, Shawn G., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

12. Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

Author

Wan, Guihong, Nguyen, Nga, Leung, Bonnie W., Rashdan, Hannah, Tang, Kimberly, Roster, Katie, Collier, Michael R., Ugwu-Dike, Pearl O., Raval, Neel S., Alexander, Nora A., Jairath, Ruple, Phillipps, Jordan, Amadife, Munachimso, Zhang, Shijia, Gusev, Alexander, Chen, Steven T., Reynolds, Kerry L., LeBoeuf, Nicole R., Kwatra, Shawn G., and Semenov, Yevgeniy R.

Published
2024
Full Text
View/download PDF

13. Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study

Author

Leung, Bonnie W., primary, Collier, Michael Ryan, additional, Tiu, Bruce C., additional, Wan, Guihong, additional, Nguyen, Nga, additional, Tang, Kimberly, additional, Zhang, Shijia, additional, Chen, Wenxin, additional, Chen, Steven T., additional, LeBoeuf, Nicole R., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

15. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study

Author

Leung, Bonnie W., primary, Wan, Guihong, additional, Nguyen, Nga, additional, Rashdan, Hannah, additional, Zhang, Shijia, additional, Chen, Wenxin, additional, Cohen, Sonia, additional, Boland, Genevieve M., additional, Sullivan, Ryan J., additional, Fadden, Riley M., additional, Kaufman, Howard L., additional, Kwatra, Shawn G., additional, LeBoeuf, Nicole R., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

16. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study

Author

Zhang, Shijia, primary, Tang, Kimberly, additional, Wan, Guihong, additional, Nguyen, Nga, additional, Lu, Chenyue, additional, Ugwu-Dike, Pearl, additional, Raval, Neel, additional, Seo, Jayhyun, additional, Alexander, Nora A., additional, Jairath, Ruple, additional, Phillipps, Jordan, additional, Leung, Bonnie W., additional, Roster, Kathleen, additional, Chen, Wenxin, additional, Zubiri, Leyre, additional, Boland, Genevieve, additional, Chen, Steven T., additional, Tsao, Hensin, additional, Demehri, Shadmehr, additional, LeBoeuf, Nicole R., additional, Reynolds, Kerry L., additional, Yu, Kun-Hsing, additional, Gusev, Alexander, additional, Kwatra, Shawn G., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

18. Surgical margin reduction in excision of cutaneous melanoma: A retrospective analysis.

Author

Rajeh, Ahmad, Roster, Katie, Nguyen, Nga, Leung, Bonnie W., Rashdan, Hannah, and Semenov, Yevgeniy R.

Subjects
*SURGICAL margin, *SURGICAL excision, *RETROSPECTIVE studies, *MELANOMA, *PROPORTIONAL hazards models
Abstract

This article presents the findings of a study on the effects of reducing surgical margins in the excision of cutaneous melanoma. The study compared outcomes of excision with reduced margins to those recommended by the American National Comprehensive Cancer Network (NCCN). The analysis included 1825 patients with early-stage melanoma. The results showed that while some cases deviated from recommended margins, particularly in the head and neck region, margin reduction did not independently lead to worse recurrence-free survival or overall survival. The study emphasizes the difficulty of achieving sufficient margin control in anatomically complex and functionally important areas. Further research is needed to validate these findings and guide clinical practice. [Extracted from the article]

Published
2024
Full Text
View/download PDF

19. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study.

Author

Wan G, Nguyen N, Leung BW, Rashdan H, Tang K, Roster K, Collier MR, Ugwu-Dike PO, Raval NS, Alexander NA, Jairath R, Phillipps J, Amadife M, Zhang S, Gusev A, Chen ST, Reynolds KL, LeBoeuf NR, Kwatra SG, and Semenov YR

Abstract

Background: Relationships between pre-existing inflammatory diseases (pIDs) and cutaneous immune-related adverse events (cirAEs) have not been well-studied. This study is to investigate associations between pIDs and cirAEs among immune-checkpoint inhibitor (ICI) recipients at the Mass General Brigham healthcare system., Methods: Electronic health records were reviewed to ascertain cirAE status. Patients' pID status was determined using International Classification of Diseases (ICD) codes. Cox proportional hazard, logistic regression, and linear regression models were performed., Results: Among 3607 ICI recipients, 1354 had pIDs, and 672 developed cirAEs. After covariate adjustments, patients with cutaneous pIDs (HR:1.56, p<0.001) or both cutaneous and non-cutaneous pIDs (HR:1.76, p<0.001) had increased cirAE risk in contrast to patients with non-cutaneous pIDs alone (HR:1.01, p=0.9). In adjusted ordinal logistic regression modeling, cutaneous pIDs (OR:1.55, p<0.0001) and the presence of both cutaneous pIDs and non-cutaneous pIDs (OR:1.71, p=0.002) were associated with increased cirAE severity. The time to cirAE onset was different between the cutaneous pID group and the non-cutaneous pID group (Mean: 98 vs. 146 days, p=0.021; Beta: -0.11, p=0.033)., Conclusions: ICI recipients with cutaneous pIDs should have increased clinical monitoring due to their increased risk of cirAE development, severity, and earlier onset.

Published
2023
Full Text
View/download PDF

20. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.

Author

Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, and Semenov YR

Abstract

Background: Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear., Objective: To investigate the association of cirAEs with survival among ICI recipients., Methods: ICI recipients were identified from the Mass General Brigham healthcare system (MGB) and Dana-Farber Cancer Institute (DFCI). Patient charts were reviewed for cirAE development within 2 years after ICI initiation. Multivariate time-varying Cox proportional hazards models, adjusted for age, sex, race/ethnicity, Charlson Comorbidity Index, ICI type, cancer type, and year of ICI initiation were utilized to investigate the impact of cirAE development on overall survival., Results: Of the 3,731 ICI recipients, 18.1% developed a cirAE. 6-month landmark analysis and time-varying Cox proportional hazards models demonstrated that patients who developed cirAEs were associated with decreased mortality (HR=0.87,p=0.027), particularly in melanoma patients (HR=0.67,p=0.003). Among individual morphologies, lichenoid eruption (HR=0.51,p<0.001), psoriasiform eruption (HR=0.52,p=0.005), vitiligo (HR=0.29,p=0.007), isolated pruritus without visible manifestation of rash (HR=0.71,p=0.007), acneiform eruption (HR =0.34,p=0.025), and non-specific rash (HR=0.68, p<0.001) were significantly associated with better survival after multiple comparisons adjustment., Limitations: Retrospective design; single geography., Conclusion: CirAE development is associated with improved survival among ICI recipients, especially melanoma patients., Capsule Summary: Patients on immune checkpoint inhibitors (ICIs) who developed cutaneous immune-related adverse events (cirAEs) had favorable outcomes. This was especially notable for melanoma patients who had cirAEs, both those with vitiligo and other morphologies.Development of cirAEs in ICI-treated patients can be used to prognosticate survival and guide treatment decisions.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results